WO2007117911A3 - Novel formulations - Google Patents

Novel formulations Download PDF

Info

Publication number
WO2007117911A3
WO2007117911A3 PCT/US2007/064512 US2007064512W WO2007117911A3 WO 2007117911 A3 WO2007117911 A3 WO 2007117911A3 US 2007064512 W US2007064512 W US 2007064512W WO 2007117911 A3 WO2007117911 A3 WO 2007117911A3
Authority
WO
WIPO (PCT)
Prior art keywords
novel formulations
formula
heptafluoro
tetrafluoroethane
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/064512
Other languages
French (fr)
Other versions
WO2007117911A2 (en
Inventor
John T. Capecchi
James S. Stefely
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3M Innovative Properties Co
Original Assignee
3M Innovative Properties Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3M Innovative Properties Co filed Critical 3M Innovative Properties Co
Priority to JP2009501713A priority Critical patent/JP2009532339A/en
Priority to US12/293,205 priority patent/US20090123391A1/en
Priority to CA002646578A priority patent/CA2646578A1/en
Priority to EP07759008A priority patent/EP1996158A2/en
Priority to AU2007234990A priority patent/AU2007234990A1/en
Publication of WO2007117911A2 publication Critical patent/WO2007117911A2/en
Anticipated expiration legal-status Critical
Publication of WO2007117911A3 publication Critical patent/WO2007117911A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A pharmaceutical aerosol formulation includes a therapeutically effective amount of particulate medicament of formula (I) or a solvate thereof, a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoro-n-propane or mixtures thereof, and a biocompatible polymer comprising one or more compounds of formula (II)
PCT/US2007/064512 2006-03-22 2007-03-21 Novel formulations Ceased WO2007117911A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2009501713A JP2009532339A (en) 2006-03-22 2007-03-21 New formulation
US12/293,205 US20090123391A1 (en) 2006-03-22 2007-03-21 Novel Formulations
CA002646578A CA2646578A1 (en) 2006-03-22 2007-03-21 Novel formulations
EP07759008A EP1996158A2 (en) 2006-03-22 2007-03-21 Novel formulations
AU2007234990A AU2007234990A1 (en) 2006-03-22 2007-03-21 Novel formulations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78467006P 2006-03-22 2006-03-22
US60/784,670 2006-03-22

Publications (2)

Publication Number Publication Date
WO2007117911A2 WO2007117911A2 (en) 2007-10-18
WO2007117911A3 true WO2007117911A3 (en) 2011-07-21

Family

ID=38581741

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/064512 Ceased WO2007117911A2 (en) 2006-03-22 2007-03-21 Novel formulations

Country Status (6)

Country Link
US (1) US20090123391A1 (en)
EP (1) EP1996158A2 (en)
JP (1) JP2009532339A (en)
AU (1) AU2007234990A1 (en)
CA (1) CA2646578A1 (en)
WO (1) WO2007117911A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3578169T (en) 2009-02-26 2024-08-26 Glaxo Group Limited Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
WO2011136753A1 (en) * 2010-04-26 2011-11-03 Mahmut Bilgic Combination of carmoterol and fluticasone for use in the treatment respiratory diseases
JP2021527054A (en) * 2018-06-07 2021-10-11 キンデーバ ドラッグ デリバリー リミティド パートナーシップ Fluticasone and vilanterol preparations and inhalers

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5569450A (en) * 1993-03-17 1996-10-29 Minnesota Mining And Manufacturing Company Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid
WO2002012265A1 (en) * 2000-08-05 2002-02-14 Glaxo Group Limited 6.ALPHA., 9.ALPHA.-DIFLUORO-17.ALPHA.-`(2-FURANYLCARBOXYL) OXY!-11.BETA.-HYDROXY-16.ALPHA.-METHYL-3-OXO-ANDROST-1,4,-DIENE-17-CARBOTHIOIC ACID S-FLUOROMETHYL ESTER AS AN ANTI-INFLAMMATORY AGENT
US6416742B1 (en) * 1997-02-07 2002-07-09 3M Innovative Properties Company Medicinal aerosol solution formulation with biocompatible polymer
US20050152845A1 (en) * 2002-02-04 2005-07-14 Keith Biggadike Amorphous fluticasone 2-furoate, pharmaceutical compositions thereof and its conversion to the crystalline unsolvated form

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5569450A (en) * 1993-03-17 1996-10-29 Minnesota Mining And Manufacturing Company Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid
US6416742B1 (en) * 1997-02-07 2002-07-09 3M Innovative Properties Company Medicinal aerosol solution formulation with biocompatible polymer
WO2002012265A1 (en) * 2000-08-05 2002-02-14 Glaxo Group Limited 6.ALPHA., 9.ALPHA.-DIFLUORO-17.ALPHA.-`(2-FURANYLCARBOXYL) OXY!-11.BETA.-HYDROXY-16.ALPHA.-METHYL-3-OXO-ANDROST-1,4,-DIENE-17-CARBOTHIOIC ACID S-FLUOROMETHYL ESTER AS AN ANTI-INFLAMMATORY AGENT
US20050152845A1 (en) * 2002-02-04 2005-07-14 Keith Biggadike Amorphous fluticasone 2-furoate, pharmaceutical compositions thereof and its conversion to the crystalline unsolvated form

Also Published As

Publication number Publication date
EP1996158A2 (en) 2008-12-03
WO2007117911A2 (en) 2007-10-18
JP2009532339A (en) 2009-09-10
US20090123391A1 (en) 2009-05-14
CA2646578A1 (en) 2007-10-18
AU2007234990A1 (en) 2007-10-18

Similar Documents

Publication Publication Date Title
IL177283A (en) Pyrazolopyrimidine compounds, use thereof for the preparation of medicaments and pharmaceutical compositions comprising same
IL176236A (en) Heterocyclic compounds, pharmaceutical compositions comprising same and use thereof for preparation of medicaments
IL221770A (en) Adamantyl-acetamide derivatives, pharmaceutical compositions comprising same and use thereof for preparation of medicaments
IL164699A (en) Derivatives of diketohydrazine compounds and pharmaceutical compositions and medicaments containing the compounds as the active ingredient
WO2007096151A3 (en) Inhibitors of p38-kinase for treatment of pulmonary hypertension
WO2008063910A3 (en) Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions
IL204052A (en) 1,1,1- trifluoro-2- hydroxy-3- phenylpropane derivatives, process for their manufacture, pharmaceutical compositions comprising the same and uses thereof for the preparation of medicaments
WO2005094810A3 (en) Novel pharmaceutical compositions
ZA200805027B (en) Use of film-forming hair-care polymers from the group of polyurethanes and pharmaceutical preparations and plasters containing said polymers
WO2008006795A3 (en) Indole compounds
SE0302192D0 (en) Novel compounds
DE602004011966D1 (en) Heterocyclylverbindungen
WO2005115470A3 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING β-CARBOLINE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF CANCER
WO2007090661A3 (en) Active substance combination comprising azolylcarbinol compounds
WO2008101173A3 (en) Biodegradable compositions and materials
SE0402925D0 (en) Novel Compounds
NO20083759L (en) Dosage aerosols for administration of pharmaceutical compositions
WO2007117911A3 (en) Novel formulations
WO2004091591A3 (en) Nutritional or therapeutic composition containing the compound oleuropeine or one of the derivatives thereof
WO2005065639A3 (en) Novel pharmaceutical compositions
AU2002356646A1 (en) Pharmaceutical compositions for the pulmonary delivery of aztreonam
WO2008004100A9 (en) Therapeutic compounds
WO2007075794A3 (en) Oral formulations comprising tigecycline
WO2005030142A3 (en) Rifalazil formulations
ATE353231T1 (en) PHARMACEUTICAL COMPOSITIONS

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 12293205

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2646578

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009501713

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007234990

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007759008

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2007234990

Country of ref document: AU

Date of ref document: 20070321

Kind code of ref document: A